Phase II Study of Combined 5-Fluorouracil/ Ginkgo biloba Extract (GBE 761 ONC) Therapy in 5-Fluorouracil Pretreated Patients with Advanced Colorectal Cancer
✍ Scribed by B. Hauns; B. Häring; S. Köhler; K. Mross; C. Unger
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 782 KB
- Volume
- 15
- Category
- Article
- ISSN
- 0951-418X
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Background. In a previous Phase I1 trial, the authors showed that a weekly continuous infusion of 5-fluorouracil (5-FU) at a dose of 3.5 g/mz for 48 hours is an active treatment for advanced colorectal cancer. The overall response rate was 38.5%, and the median survival was 12 months. These data wer
n the article published in Cancer entitled "Phase I1 study of 5-fluoro-I uracil and folinic acid in the treatment of patients with advanced gastric cancer. A Southwest Oncology Group Study,"' the authors erroneously quoted the results of our study and we request a correction. In the results of our